Last reviewed · How we verify
WPV01
WPV01 is a small molecule drug that targets the SARS-CoV-2 main protease.
WPV01 is a small molecule drug that targets the SARS-CoV-2 main protease. Used for Treatment of COVID-19.
At a glance
| Generic name | WPV01 |
|---|---|
| Sponsor | Westlake Pharmaceuticals (Hangzhou) Co., Ltd. |
| Drug class | SARS-CoV-2 main protease inhibitor |
| Target | SARS-CoV-2 main protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
WPV01 works by inhibiting the SARS-CoV-2 main protease, which is essential for the replication of the virus. This inhibition prevents the virus from replicating and reduces the severity of the disease. WPV01 has shown promise in preclinical studies as a potential treatment for COVID-19.
Approved indications
- Treatment of COVID-19
Common side effects
- Nausea
- Headache
- Fatigue
Key clinical trials
- [14C] Study to Investigate the Mass Balance and Biotransformation of WPV01 in Healthy Adult Chinese Male Participants (PHASE1)
- Study of WPV01 in Healthy Subjects (PHASE1)
- Phase III Clinical Study Evaluating the Efficacy and Safety of WPV01 in Patients With Mild/Moderate COVID-19 (PHASE3)
- Study of WPV01 Compared With Placebo in Patients With Mild/Moderate COVID-19 Infection (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- WPV01 CI brief — competitive landscape report
- WPV01 updates RSS · CI watch RSS
- Westlake Pharmaceuticals (Hangzhou) Co., Ltd. portfolio CI